Standpoint Research downgraded Endo Pharmaceuticals Holdings Inc (NASDAQ: ENDP) from Hold to Buy.

Analyst Ronnie Moas comments, "ENDP was ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE